World Parkinson Coalition

1359 Broadway, Suite 1509
New York, NY 10018
USA

Save the Date!
May 24-27, 2026

WPC CHAMPION PARTNERS

Parkinson's Foundation

PARKINSON'S UK

Fight Parkinson's
Together we can

apda AMERICAN PARKINSON DISEASE ASSOCIATION

Houston Area Parkinson Society

PARKINSON ASSOCIATION OF THE CAROLINAS

Parkinson Canada

SHARE

LEARN MORE AT WPC2026.org

FOLLOW US !

See you in Phoenix!

7th WORLD PARKINSON CONGRESS

Phoenix, AZ, USA

MAY 24 – 27, 2026

PHOENIX CONVENTION CENTER

WPC2026.org

WorldPDCongress worldpdcongress #WPC2026

ABOUT THE...

WORLD PARKINSON COALITION®

The Coalition is a non-profit organization that has been bringing the global Parkinson disease (PD) community together since 2006. We believe that we'll discover new treatments, advance our understanding of PD, and ultimately find a cure faster if the work is done collaboratively and inclusively with all people touched by PD working together.

ABOUT THE...

WORLD PARKINSON CONGRESS

The 7th World Parkinson Congress (WPC 2026) will be held from May 24 – 27, 2026 in Phoenix, Arizona at the Phoenix Convention Center. This unique, international, interdisciplinary event will showcase the latest developments in the world of PD. The WPC 2026 is open to all people touched by PD, including researchers, neurologists, physicians, rehabilitation therapists, nurses, social workers, nutritionist, people with PD, care partners, and others.

A diverse four-day accredited program will cover topics of interest to all members of the community, including scientific and clinical research, rehabilitation research, education and training, best-care models, and quality of life issues.

Find details at WPC2026.org

WHO SHOULD ATTEND?

- Neuroscientists, neurologists, community physicians & geriatricians
- Nurses, APPs, rehabilitation therapists, social workers, nutritionists & others
- People with Parkinson disease
- Care partners/caregivers/family
- Nonprofit organization staff
- Pharmaceutical industry leaders & staff
- Government and policy representatives

KEY DATES

2024	MAY 31	Ambassador Applications close
	SEPTEMBER 10	Sponsor & Exhibit Prospectus available
2025	APRIL 7	Volunteer Application opens
	JUNE 2	Video & Song Competitions open
	AUGUST 1	Travel Grants Application open
	AUGUST 12	Abstract Submission opens
	SEPTEMBER 4	Registration & Hotel Bookings opens
	OCTOBER 2	Abstract/Travel Grant Submissions close
2026	MARCH	Late Breaking Abstracts
	MAY 24-27, 2026	**7th World Parkinson Congress**

TRAVEL GRANTS PROGRAM

Thanks to individuals and corporate donations, a limited number of travel grants will be offered to:

- Junior investigators / Clinicians with an accepted abstract
- Health professionals from emerging parts of the world who treat people with PD
- People with Parknson disease who are active in their communities

Hari Subramaniam

Joanne Ruby

Christopher Flores

Exercise and PD



Exercise and PD



Exercise and PD



7th World Parkinson Congress
Phoenix, AZ, USA

DONATE CONTACT US Enter sea

WORLD PA

ABOUT | PROGRAM | ABSTRACTS | REGISTRATION | TRAVEL & HOTELS | SU

- Program-At-A-Glance
- Scientific Program
- Faculty
- Session Descriptions
- Clinical Research Village
- Wellness Program
  - Renewal Room
  - Mindfulness & Meditation Room
  - Lunch & Learn
  - Family & Care Partner Classroom & Lounge
  - Support Group Leader Lounge
  - Massage and Reiki Room
  - Pickleball Room
  - Ping Pong room
- Creativity Programs
- Networking Opportunities
- Special Workshops
- Satellite Programs
- Awards
- Corporate Sessions

Renewa

CLASS S

ABOUT

The **Renewal Room** is open to all delegates who wish to exercise their bodies, voices, and minds to restore or revitalize themselves during the Congress. The program includes engaging sessions each day to get people **moving and to improve balance, gait, voice amplitude, breath,**

Disease Modifying Trials (DMT)



Alpha Synuclein



Stem cells


7th World Parkinson Congress Phoenix, AZ, USA
Bemdaneprocel — Stem Cell Therapy for Parkinson's
WPC 2026.org
How bemdaneprocel works
Source: Human embryonic pluripotent stem cells
Delivery: Surgical implantation into post-commissural putamen bilaterally
After implantation: Precursors continue maturing into functional DA neurons in situ
Goal: Rebuild the dopaminergic neural circuits PD has dismantled
Open-label · Multi-center · Two dose cohorts
exPDite — Phase 1 (n=12, 18 months)
Secondary outcomes:
−23 points MDS-UPDRS III (high-dose, off-med)
+2.7 hr Good On-Time/day vs baseline
0 cell-related No cell-product-related AEs through 18 mo
exPDite-2 — Phase 3 ★
Randomized · Sham surgery-controlled · Double-blind
~102 patients · First patient: September 2025
Primary: Good On-Time · Data readout 2027
Tabar V et al., Nature 2025 | exPDite Phase 1: NCT04802733 | exPDite-2 Phase 3: NCT06309577
#WPC2026 @worldpdcongress

Summary of Published Clinical Trials

Clinical trial	Location	Cell source	Design	Adjunct immunosuppression	n	Results
Autologous iPS-derived DA cells *(Schweitzer et al New Engl J Med 2021)*	USA (Boston/ New York)	autologous mDAPs (iPS: skin fibroblast origin) d.28	"n of one" Open label Bilateral staged transplants No adjunct immunosuppression Follow up to 24 months reported	None	1	Safe/tolerable Improved UPDRS-III "off" Increased FDOPA uptake by PET
hESC-derived DA cells: Bemdaneprocel *(Tabar et al Nature 2025)*	USA/Canada (New York, Irvine, Toronto)	allogeneic (hESC line) d.16	Phase 1 Open label Bilateral single session transplant Dose escalation Primary endpoint 12 months and follow up to 24 months reported	Basilixumab, predaisone, tacrolimus for 1 year	12	Safe/tolerable Improved UPDRS-III "off" * Improved "off" time" * Increased FDOPA uptake by PET *greater effects in high dose cohort
iPS-derived DA cells: *(Sawimoto et al Nature 2025)*	Japan (Kyoto)	allogeneic (iPS: peripheral blood origin) Cell-sorting (corin) d. 11-13	Phase 1/2 Open label Bilateral single session transplant Dose escalation Adjunct immunosuppression Primary endpoint and follow up to 24 months reported	Tacrolimus for 15 months (reduced at 12 months)	7	Safe/tolerable Improved UPDRS-III "off"; Increased FDOPA uptake by PET


7th World PARKINSON CONGRESS
Phoenix, AZ, USA
WPC 2026.org
Other Selected Clinical Trials
Clinical trial | Location | Cell source | Design | n
Allife Medical Science and Technology | China | iPSC Allogeneic | Phase 1 | 10
DAP001 Aspen Neuroscience (ASPIRO) | USA | iPSC Autologous | Phase 1/2 | 7
iRegene Therapeutics: NouvNeu001 | China | iPSC Allogeneic | Phase 1 | 6
Kenai: RNDP-001 | USA | iPSC Allogeneic | Phase 1b/2a | 12
MGH | USA | iPSC Autologous | Phase 1 | 8
MGH | USA | iPSC Autologous | Phase 1 | 6
Nuwacell Biotechnnologies NCR201 | China | iPSC Autologous | Phase 1 | 48 est.
S. Biomedics | South Korea | hESC | Phase 1 Long term follow up | 12
STEM-PD NovoNordisk | UK/Sweden | hESC | Phase 1 | 8
XellSmart Biomedical | China | iPSC Autologous | Phase 1 | 3
Loring JF. Autologous Induced Pluripotent Stem Cell-Derived Neurons to Treat Parkinson's Disease. Stem Cells Dev. 2018;27(14):958-9
Kirkeby (2023) Cell Stem Cell Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the tr of Parkinson's disease, STEM-PD 5;30:1299-1314.e9.
#WPC2026 @worldpdcongress

7th World Parkinson Congress Phoenix, AZ, USA

Ambroxol

WPC 2026.org

A repurposed cough medicine

The GBA1 pathway — why it matters

GBA1 mutation: ~10–15% of PD patients

GCase enzyme: Clears α-synuclein aggregates

Ambroxol: Rescues misfolded GCase → lysosome

Active trials — motor outcomes

GREAT — Phase 2 (n=80)
80 GBA1-PD patients
Ambroxol 1800mg/day vs placebo | 48 weeks
Primary: MDS-UPDRS III

ASPro-PD — Phase 3 ★ (NCT05778617)
330 patients (GBA1+ and GBA1−)
Ambroxol vs placebo | 2 years
Primary: MDS-UPDRS I + II + III
UK sites only · No US sites

GREAT Phase 2: NCT05830396 | ASPro-PD Phase 3: NCT05778617

Prodromal PD



Women and PD


Weill Cornell Medicine
Neurological Surgery
PD AVENGERS
Understanding the unmet needs of women with Parkinson's pre and post diagnosis to inform care, support and research
Soania Mathur MD[1,4], Kristi La Monica PhD[3], Kat Hill CNM-NP, with Roberta Marongiu PhD[2] Deyran Paredes[4], Monica Korell MPH[4], Caroline M Tanner MD PhD[4], Helen Matthews[5].
[1]PD Avengers, Vancouver, BC Canada, [2]Department of Neurological Surgery, Weill Cornell Medicine, New York, NY., [3]Russell Sage College, Albany, NY., [4]University of California San Francisco, San Francisco, CA., [5]Cure Parkinson's Foundation, London, UK.
CURE PARKINSON'S
FOX INSIGHT
Introduction
Written by women with Parkinson's (PD) for women with PD in partnership with Fox Insight (FI), this initiative comprises a comprehensive series of surveys mapping women's experiences across key life stages, including pre-, peri-, and post-menopause, and the psychosocial impact of PD. A companion survey addresses fertility, pregnancy, and childbirth before and after diagnosis. Conducted within FI, this represents the first large-scale effort to systematically capture women's lived experiences with PD across these critical life stages. Women with Parkinson's disease (PD) experience unique hormonal, reproductive, and psychosocial challenges that remain under-recognized in clinical care and may significantly affect quality of life and therapy effectiveness.
The study team—Dr. Soania Mathur (family physician), Kat Hill (maternity nurse), and Dr. Kristi LaMonica (researcher)— collaborated with an advisory group of women with young-onset PD, originated out of a World Parkinson's Congress working group, whose clinical and lived experience informed survey design. The work was supported by Helen Matthews (Cure Parkinson's), the FI team, and Dr. Roberta Marongiu, who contributed to data analysis.
Methodology & Demographics
Listening sessions with PD women on their experience before and after diagnosis informed survey design. Questions addressed symptom evolution and medication adjustments during key hormonal phases: pre-, peri-, and post-menopause, and across pregnancy, childbirth, and postpartum. In collaboration with the Michael J. Fox Foundation, and using the Fox Insight platform, the surveys were piloted in North America and the UK to ensure linguistic and cultural alignment.
(a) Demographics tables for the three questionnaires
(b) Age distribution of women with PD who took the FHHL questionnaire
Overall Age Distribution
Acknowledgements
Results
Timing of Parkinson's diagnosis
What life phase currently applies to you?
Conclusions
There is a striking interest from women under-recognized by healthcare providers with PD to share their experiences highlighting unmet needs that remain. These span the life course - from delayed diagnosis to inadequate support during fertility, pregnancy, and menopause. Ongoing collaboration with researchers aims to leverage this unique dataset to advance understanding of hormonal, reproductive, and neurological health interactions in women with PD, and to guide more inclusive, responsive care.

Women and PD


Tracking symptoms and medications in women with Parkinson's disease
Sarah Moore [1,2], Lucy Collins Stack [2,3], Richelle Flanagan [4], Rene Reinbacher [4], Aonghus Lavelle [3], Aideen M. Sullivan [1,2*]
1. Department of Pharmacology and Therapeutics, School of Medicine, University College Cork, Ireland
2. Department of Anatomy and Neuroscience, School of Medicine, University College Cork, Ireland
3. Parkinson's Disease Research Cluster, University College Cork, Ireland
4. My Moves Matter, Dublin, Ireland
BACKGROUND
METHODS
RESULTS
CONCLUSIONS
UCC FUTURES
Future Ageing and Brain Science
Securing Our Future Through Research Excellence
Corresponding Author:
Prof. Aideen Sullivan: a.sullivan@ucc.ie
The authors declare no conflict of interest.

Elements of a Dance for PD class


TICKETS


HOPE
You Are Not Alone
Nacogdoches Texas
Support Group
VICTORY
DAVIS PHINNEY